This content is restricted to site members. If you are an existing user, please log in. New users may register below.
US FDA issues Form 483 observations for Sun Pharma’s Halol site in Gujarat
(G.N.S) Dt. 23 Ahmedabad Sun Pharma, India’s largest drug maker on Friday said US FDA has issued three Form 483 observations for its Halol site in Gujarat. The company didn’t disclose the nature of these observations. A Form 483 is issued by the US FDA inspectors at the end of